An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease

Gastroenterology

Volumn 109, Issue 6, 1995, Pages 1808-1817

  Sandborn, William J ^a   Van Os, Erik C ^a   Zins, Bradley J ^a   Tremaine, William J ^a   Mays, Dennis C ^a   Lipsky, James J ^a  

^a MAYO CLINIC   (United States)

Author keywords

6 mercaptopurine; 6 methylmercaptopurine; 6 MMP; 6 MP; 6 TGN; 6 thioguanine nucleotides; acute lymphocytic leukemia; AZA; azathioprine; high performance liquid chromatography; HPLC; RBCs; red blood cells; thiopurine methyltransferase; TPMT; WBCs; white blood cells

Indexed keywords

AZATHIOPRINE; CIPROFLOXACIN; MERCAPTOPURINE; METHYLPREDNISOLONE; METRONIDAZOLE; PREDNISONE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CROHN DISEASE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG METABOLISM; DRUG SAFETY; FEMALE; FISTULA; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MALE; ORAL DRUG ADMINISTRATION; PANCREATITIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0028881322     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/0016-5085(95)90747-5     Document Type: Article

References (50)

1. Controlled trial of azathioprine in Crohn's disease
2. National cooperative Crohn's disease study: results of drug treatment
3. Treatment of Crohn's disease with azathioprine: a controlled evaluation
4. Azathioprine combined with prednisolone or monotherapy with prednisone in active Crohn's disease
5. A double blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn's disease (abstr)
6. Controlled trial of azathioprine in Crohn's disease
7. Treatment of Crohn's disease with 6-mercaptopurine
8. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease
9. A controlled trial of azathioprine in Crohn's disease
10. Azathioprine and 6-Mercaptopurine in Crohn Disease
11. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease
12. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years experience
13. 6-mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity
14. Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity
15. The comparative metabolism of Imuran and 6-mercaptopurine in man
16. The metabolic fate of the methylnitroimidazole moiety of azathioprine in the rat
17. The clinical pharmacology of 6-mercaptopurine
18. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity
19. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
20. Mercaptopurine metabolism and the risk of relapse in childhood lymphoblastic leukaemia
21. Childhood leukemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia
22. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism
23. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations
24. Variable bioavailability of oral mercaptopurine
25. Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations
26. Azathioprine pharmacokinetics following single dose IV, oral, delayed-release oral and rectal foam administration (abstr)
27. Azathioprine metabolism in kidney transplant recipients
28. Phase 1 in a clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion
29. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia
30. Metabolism of azathioprine to 6-thioguanine nucleotides in patients with pemphigus vulgaris
31. Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients
32. Bioavailability of low-dose versus high-dose 6-mercaptopurine
33. A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors
34. Development of a Crohn's disease activity index
35. Rederived values of the eight co-efficients of the Crohn's disease activity index (CDAI)
36. Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine, and 6-thioguanine, in human red blood cells
37. A reversed-phase high-performance liquid chromatography approach in determining total red blood cell concentrations of 6-thioguanine, 6-mercaptopurine, methylthioguanine, and methylmercaptopurine in a patient receiving thiopurine therapy
38. Favorable effect of 6-mercaptopurine on fistulae in Crohn's disease
39. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A
40. Efficacy of cyclosporine in treatment of fistula of Crohn's disease
41. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease
42. A double-blind, randomized, placebo-controlled trial of methotrexate in Crohn's disease (abstr)
43. Methotrexate for the Treatment of Crohn's Disease
44. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease
45. Clinical, biological and endoscopic picture of attacks of Crohn's disease
46. Cyclosporine in severe ulcerative colitis refractory to steroid therapy
47. Reversed-phase high-performance liquid chromatographic approach to determine total lymphocyte concentrations of 6-thioguanine, methylmercaptopurine and methylthioguanine in humans
48. 6-Mercaptopurine (6-MP) metabolite measurement in IBD patients' neutrophils correlates with drug efficacy (abstr)
49. Pancytopenia related to azathioprine—an enzyme deficiency caused by a common genetic polymorphism: a review
50. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients